Eli Lilly Management

Management criteria checks 2/4

Eli Lilly's CEO is Dave Ricks, appointed in Jan 2017, has a tenure of 7.83 years. total yearly compensation is $26.57M, comprised of 6.1% salary and 93.9% bonuses, including company stock and options. directly owns 0.067% of the company’s shares, worth CLP446.36B. The average tenure of the management team and the board of directors is 6.2 years and 8.4 years respectively.

Key information

Dave Ricks

Chief executive officer

US$26.6m

Total compensation

CEO salary percentage	6.1%
CEO tenure	7.8yrs
CEO ownership	0.07%
Management average tenure	6.2yrs
Board average tenure	8.4yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Dave Ricks's remuneration changed compared to Eli Lilly's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2024	n/a	n/a	US$8b
Jun 30 2024	n/a	n/a	US$7b
Mar 31 2024	n/a	n/a	US$6b
Dec 31 2023	US$27m	US$2m	US$5b
Sep 30 2023	n/a	n/a	US$5b
Jun 30 2023	n/a	n/a	US$6b
Mar 31 2023	n/a	n/a	US$6b
Dec 31 2022	US$21m	US$2m	US$6b
Sep 30 2022	n/a	n/a	US$6b
Jun 30 2022	n/a	n/a	US$6b
Mar 31 2022	n/a	n/a	US$6b
Dec 31 2021	US$22m	US$2m	US$6b
Sep 30 2021	n/a	n/a	US$6b
Jun 30 2021	n/a	n/a	US$6b
Mar 31 2021	n/a	n/a	US$6b
Dec 31 2020	US$24m	US$1m	US$6b
Sep 30 2020	n/a	n/a	US$6b
Jun 30 2020	n/a	n/a	US$6b
Mar 31 2020	n/a	n/a	US$6b
Dec 31 2019	US$21m	US$1m	US$5b
Sep 30 2019	n/a	n/a	US$4b
Jun 30 2019	n/a	n/a	US$4b
Mar 31 2019	n/a	n/a	US$3b
Dec 31 2018	US$17m	US$1m	US$3b
Sep 30 2018	n/a	n/a	US$372m
Jun 30 2018	n/a	n/a	-US$166m
Mar 31 2018	n/a	n/a	US$1b
Dec 31 2017	US$16m	US$1m	-US$86m

Compensation vs Market: Dave's total compensation ($USD26.57M) is above average for companies of similar size in the CL market ($USD5.75M).

Compensation vs Earnings: Dave's compensation has increased by more than 20% in the past year.

CEO

Dave Ricks (56 yo)

7.8yrs

Tenure

US$26,565,732

Compensation

Mr. David A. Ricks, also known as Dave, has been a Director of Adobe Inc. since April 12, 2018 and previously served as its Director since June 2017. He served as a Director of Elanco Animal Health Incorpo...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
David Ricks	Chairman	7.8yrs	US$26.57m	0.067% CLP 446.4b
Daniel Skovronsky	EVP, Chief Scientific Officer and President of Lilly Research Laboratories & Lilly immunology	6.4yrs	US$11.85m	0.021% CLP 142.7b
Anat Hakim	Executive VP	4.8yrs	US$7.01m	0.0034% CLP 22.4b
Jacob Van Naarden	Executive VP & President of Loxo	no data	US$4.89m	0.0023% CLP 15.1b
Lucas Montarce	Executive VP & CFO	less than a year	no data	0.0012% CLP 8.2b
Donald Zakrowski	Senior VP of Finance & Chief Accounting Officer	12yrs	no data	0.00080% CLP 5.3b
Diogo Rau	EVP & Chief Information and Digital Officer	3.5yrs	US$5.10m	0.0012% CLP 8.2b
Alonzo Weems	EVP of Enterprise Risk Management and Chief Ethics & Compliance Officer	3.4yrs	no data	0.00088% CLP 5.8b
Eric Dozier	Executive Vice President of Human Resources & Diversity	1.9yrs	no data	0.00093% CLP 6.2b
Jeffrey Simmons	Senior VP & President of Elanco Animal Health	16.8yrs	US$5.38m	no data
W. Moody	SVP of Global Active Pharmaceutical Ingredient	8.3yrs	no data	no data
Anne White	EVP & President of Lilly Neuroscience	6.2yrs	no data	0.0073% CLP 48.3b

6.2yrs

Average Tenure

54yo

Average Age

Experienced Management: LLYCL's management team is seasoned and experienced (6.2 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
David Ricks	Chairman	7.8yrs	US$26.57m	0.067% CLP 446.4b
Gabrielle Greene-Sulzberger	Independent Director	3.8yrs	US$335.50k	0.00028% CLP 1.9b
Sidney Taurel	Chairman Emeritus	15.8yrs	US$13.06m	no data
Jon Erik Fyrwald	Independent Director	19yrs	US$344.88k	0.000010% CLP 66.4m
Ralph Alvarez	Independent Director	15.6yrs	US$336.00k	0.000080% CLP 531.3m
William Kaelin	Independent Director	12.4yrs	US$349.15k	0.0024% CLP 15.8b
Mary Hedley	Independent Director	2.5yrs	US$319.00k	0.000040% CLP 265.6m
Juan Luciano	Lead Independent Director	8.8yrs	US$373.00k	0.0018% CLP 11.9b
Katherine Baicker	Independent Director	12.9yrs	US$336.00k	0.0026% CLP 17.1b
Jamere Jackson	Independent Director	8.1yrs	US$345.00k	0.0010% CLP 6.8b
Karen Walker	Independent Director	5.9yrs	US$359.00k	0.00069% CLP 4.6b
Kimberly Johnson	Independent Director	3.8yrs	US$316.00k	0.00033% CLP 2.2b

8.4yrs

Average Tenure

62.5yo

Average Age

Experienced Board: LLYCL's board of directors are considered experienced (8.4 years average tenure).

Eli Lilly Management

Management criteria checks 2/4

Key information

Recent management updates

Eli Lilly and Company Announces Board Changes

Eli Lilly and Company Appoints Thomas J. Fuchs as First Chief AI Officer, Effective October 21, 2024

Eli Lilly and Co. Appoints Lucas Montarce as CFO

Eli Lilly and Company Announces Retirement of Marschall S. Runge as Independent Director, Effective August 31, 2024

Insufficient new directors

Recent updates

Frantz Law Group Files Oceanside Unified School District Lawsuit Against Eli Lily, Novo Nordisk, Sanofi, Express Scripts, CVS Caremark, and Optum RX for Insulin Pricing Scheme

Eli Lilly and Company Announces Board Changes

Eli Lilly and Company Announces Positive Phase 2 Results for muvalaplin

Eli Lilly and Company Announces Detailed Results from the Phase 3 Survey-1 Three-Year Study

Eli Lilly and Company Announces Details of Presentations At the 2024 American Society of Hematology Annual Meeting

Third quarter dividend of US$1.30 announced

Eli Lilly and Company to Present Results from Phase 3 EMBER-3 Study of Imlunestrant, an Oral SERD, and Additional Results from Its Breast Cancer Portfolio at the San Antonio Breast Cancer Symposium

Third quarter 2024 earnings released: EPS: US$1.08 (vs US$0.064 loss in 3Q 2023)

Eli Lilly and Company Revises Earnings Guidance for the Year 2024

Lilly's Mirikizumab Is First and Only IL23p19 Antagonist to Report Long-Term, Multi-Year, Sustained Efficacy and Safety Data for Both Ulcerative Colitis and Crohn's Disease

Eli Lilly and Company Declares Fourth-Quarter 2024 Dividend, Payable on December 10, 2024

Lilly's EBGLYSS (Lebrikizumab-Lbkz) Demonstrated Meaningful Improvement in Skin Clearance and Itch Relief in the Majority of Patients with Moderate-To-Severe Atopic Dermatitis Who Discontinued Dupilumab

Eli Lilly and Company to Report Q3, 2024 Results on Oct 30, 2024

Eli Lilly and Company Reports One-Year Histologic Outcomes in Phase 3 Study of Mirikizumab Compared to Ustekinumab for Crohn's Disease

Eli Lilly and Company Appoints Thomas J. Fuchs as First Chief AI Officer, Effective October 21, 2024

FDA Approves Lilly's EBGLYSS (Lebrikizumab-Lbkz) for Adults and Children 12 Years and Older with Moderate-To-Severe Atopic Dermatitis

Eli Lilly and Co. Appoints Lucas Montarce as CFO

Eli Lilly and Company Announces Positive Topline Results from the QWINT-1 and QWINT-3 Phase 3 Clinical Trials Evaluating Once Weekly Insulin Efsitora Alfa

Eli Lilly and Company Announces Positive Topline Results from the Surmount-1 Three-Year Study Evaluating the Efficacy and Safety of Tirzepatide

Eli Lilly and Company Announces Retirement of Marschall S. Runge as Independent Director, Effective August 31, 2024

Eli Lilly and Company (NYSE:LLY) completed the acquisition of Morphic Holding, Inc. (NasdaqGM:MORF) from TAS Partners, LLC, Timothy Springer, Chafen Lu and others.

Second quarter 2024 earnings released: EPS: US$3.29 (vs US$1.96 in 2Q 2023)

Eli Lilly and Company Raises Earnings Guidance Full-Year 2024

Insufficient new directors

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age